12-Month Chronic Toxicity Study of LY275585 (Human Insulin Analog) Administered Subcutaneously to Fischer 344 Rats

Abstract

The monocomponent insulin analog LY275585 was administered to Fischer 344 rats in daily subcutaneous doses of 0, 20, or 200 U/kg for 12 months. Each treatment group consisted of 30 males and 30 females, and the vehicle control group consisted of 35 of each sex. Changes related to the pharmacologic activity of LY275585 included an increase in body weight, body weight gain, food consumption, and efficacy of food utilization in male and female rats given 200 U/kg. Pharmacologically related clinical chemistry effects occurring at 200 U/kg were an increase in mean serum glucose (24 h postdose) of males and females, a slight decrease in mean serum triglyceride of females, and decreased mean serum cholesterol of males and females. Fewer effects occurred in low-dose rats (20 U/kg) and included an increase of efficiency of food utilization only in female rats, a slight decrease in mean serum triglyceride in females, and decreased mean serum cholesterol in low-dose males and females. Three male and two female rats administered 200 U/kg died during the treatment period. Death of one male was attributed to hypoglycemia. Cause of death of four other high-dose rats was either not apparent, or the result of a variety of intercurrent disease processes unrelated to treatment. Survival in the low-dose (20 U/kg) and control groups was similar; one rat in each group died prior to treatment termination. The only compound-related lesion associated with treatment was a non-dose-related enhancement of the degree and incidence of inflammation at the site of subcutaneous injection. There were no compound-related changes in background lesions including neoplasms, or in hematologic or urinalysis values. In a comparison study, pharmacokinetic profiles of LY275585 and serum glucose values were determined in groups of 30 male and female rats administered single doses of 20 or 200 U/kg. Plasma levels of LY275585 peaked after 30 min, were dose related, and were similar in male and female rats. The hypoglycemia produced in rats receiving a single dose of 20 U/kg was maximal, suggesting saturation of the insulin receptor sites at this dose. The dose of 200 U/kg of LY275585 was, therefore, a supramaximal pharmacological dose when compared to an average daily human dose of 0.5 U/kg/ d. It is concluded that no toxicologically significant changes, other than moderate injection site inflammation, occurred in Fischer 344 rats treated with LY275585 at doses of 20 and 200 U/kg for 12 months.

Keywords

human insulin analog hypoglycemia inflammatory response serum glucose

References

Bierman, E. L. , and Glomset, J. A. 1985. Disorders of lipid metabolism. In Williams textbook of endocrinology, 7th ed., ed. J. D. Wilson and D. W. Foster , pp. 1108–1136. Philadelphia: W. B. Saunders.

Bornfeldt, K. E. , Gidlof, R. A. , Wasteson, A. , Lake, M. , Skottner, A. , and Arnqvist, H. J. 1991. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34:307–313.

Brawer, J. R. , and Sonnenchein, C. 1975. Cytopathological effects of estradiol on the arcuate nucleus of the female rat. A possible mechanism for pituitary tumorigenesis. Am. J. Anat. 144:57.

Brems, D. N. , Alter, L. A. , Beckage, M. J. , et al. 1992. Altering the association properties of insulin by amino acid replacement. Protein Eng. 5:527–533.

Burns, T. H. 1974. Endocrinology. In Pathologic physiology: Mechanisms of disease, 5th ed., eds. W. A. Sodeman, Jr. , and W. A. Sodeman , pp. 865–914. Philadelphia: W. B. Saunders.

Dahl-Jorgensen, K. , Brinchmann-Hansen, O. , Hanssen, K. F. , et al. 1986. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: The Oslo study. Br. Med. J. 293:1195–1199.

DeMeyts, P. 1994. The structural basis of insulin and insulin-like growth-factor 1 receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. Diabetologia 37(suppl. 2):S135–S148.

Dideriksen, L. H. , Jorgensen, L. N. , and Dreijer, K. 1992. Carcinogenic effect on female rats after 12 months administration of insulin analogue B10 asp. Diabetes 41(suppl. 1):143A.

DiMarchi, R. D. , Mayer, J. P. , Fan, L. , Brems, D. N. , et al. 1992. Synthesis of a fast-acting insulin based on structural homology with insulin-like growth factor 1. In Peptides XII (Proc. 12th American Peptide Symp.), eds. J. A. Smith and J. E. Rivier , pp. 26–28. Leiden: Escom.

10.

Drejer, K. V. , Larsen, U. D. , Hougaard, P. , Bjorn, S. , and Gammeltoft, S. 1991. Receptor binding and tyrosine kinase activation by insulin and analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40:1488–1495.

11.

Eldridge, J. C. , Flenor-Heyser, D. G. , Extrom, P. C. , et al. 1994. Short-term effects of chlorotriazines on estrus in female Sprague-Dawley and Fischer 344 rats. J. Toxicol. Environ. Health 43:155–167.

12.

Estes, K. S. , and Simpkins, J. W. 1984. Age-related alternatives in cata-cholamine activity within micro dissected brain regions of ovariectomized Fisher 344 rats. J. Neurosci. Res. 11:405–417.

13.

Estes, K. S. , Simpkins, J. W. , and Kalra, S. P. 1982. Normal LHRH neuronal function and hyperprolactinemia in old pseudopregnant Fisher 344 rats. Neurobiol. Aging 3:247–252.

14.

Gammeltoft, S. 1984. Insulin receptors: Binding kinetics and structure-function relationship of insulin. Physiol Rev. 64:1321–1378.

15.

Gammeltoft, S. , and Drejer, K. 1991. Increased mitogenic potency of high affinity insulin analogues in mouse NIH 3T3 fibroblasts (abstr.). J. Cell. Biochem. Suppl. 15B:54.

16.

Guyton, A. C. 1991. Insulin, glucagon, and diabetes mellitus. In Textbook of medical physiology, 8th ed., pp. 855–867. Philadelphia: W. B. Saunders.

17.

Harman, S. M. , and Talbert, G. B. 1985. Aging of the reproductive system. In Handbook of the biology of aging, eds. C. E. Finch and E. I. Schneider , pp. 457–510. New York: Van Nostrand Reinhold.

18.

Howey, D. C. , Bowsher, R. R. , Brunell, R. L. , and Woodworth, J. R. 1994. [Lys (B28), Pro (B29)] Human insulin, a rapidly absorbed analogue of human insulin. Diabetes 43:396–402.

19.

Jorgensen, L. N. , Dideriksen, L. H. , and Drejer, K. 1992. Carcinogenic effect of the human insulin analogue B10 asp in female rats. Diabetologia 35 (suppl. 1):A3.

20.

King, G. L. , and Kahn, C. R. 1981. Non-parallel evolution of metabolic and growth-promoting functions of insulin. Nature 292:644–646.

21.

Kroc Collaborative Study Group . 1984. Blood glucose control and the evolution of diabetic retinopathy and albuminuria: A preliminary multicenter trial. N. Engl. J. Med. 311:365–372.

22.

LeFevre, J. , and McClintock, M. K. 1988. Reproductive senescence in female rats: A longitudinal study of individual differences in estrous cycles and behavior. Biol. Reprod. 38:780–789.

23.

Lu, K. H. , Hopper, B. R. , Vargo, T. M. , and Yen, S. S. C. 1979. Chronological changes in sex steroid, gonadotropin, and prolactin secretion in aging female rats displaying different reproductive states. Biol. Reprod. 21:193–203.

24.

McConnell, R. F. 1989. General observations on the effects of sex steroids in rodents with emphasis on long-term oral contraceptive studies. In Safety requirements for contraceptive steroids, ed. F. Michael , pp. 211–229. Cambridge: Cambridge University Press.

25.

Radziuk, J. , Canadas, B. , Davies, J. , Yang, M. , DiMarchi, R. , and Chance, R. 1991. The absorption kinetics of subcutaneously injected insulin and two monomeric analogs. Diabetes 40(suppl. 1):A465.

26.

Radziuk, J. , Davies, J. , Pye, R. , DiMarchi, R. , Shields, J. , and Chance, R. 1992. Subcutaneous absorption of fast-acting insulin analogs: Kinetics and bioeffectiveness. Diabetolegia 35(suppl. 1):A3.

27.

Santiago, J. V. 1993. Lessons for the diabetes control and complications trial. Diabetes 42:1549–1554.

28.

Sarker, D. K. , Gottschall, P. E. , and Meites, J. 1982. Damage to hypothalamic dopaminergic neurons is associated with development of prolactin-secreting pituitary tumors. Science 218:264.

29.

Shaw, W. N. , and Su, K. S. E. 1991. Biological aspects of a new human insulin analog: [Lys(B28),Pro(B29)]-human insulin. Diabetes 40(suppl. 1):464A.

30.

Slieker, L. J. , and Sundell, K. 1991. Modifications in the 28–29 position of the insulin B-chain alter binding to the IGF-1 receptor with minimal effect on insulin receptor binding. Diabetes 40(suppl. 1):168A.

31.

Slieker, L. J. , Brooke, G. S. , Chance, R. E. , et al. 1994. Insulin and IGF-1 analogs: Novel approaches to improved insulin pharmacokinetics. In Current directions in insulin-like growth factor research, ed. D. Le Roith and M. K. Raizada , pp. 25–32. New York: Plenum Press.

32.

Tukey, J. W. , Ciminera, J. L. , and Heyse, J. E. 1985. Testing the certainty of a response to increasing doses of a drug. Biometrics 41:295–301.

33.

Wise, P. M. 1987. The role of the hypothalamus in aging of the female reproductive system. J. Steroid Biochem. 27:713–719.

34.

Wolpert, H. , Slieker, L. , Sundell, K. , and King, G. 1990. Identification of an insulin analog with enhanced growth effect in aortic smooth muscle cells. Diabetes 39(suppl. 1):140A.